Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Vimpat Draws 10 Generic Entrants in December Listing; Forxiga Has Two, but Nipro AG Absent
Six APIs will see first-time generic entries in the next round of biannual generic listing on December 5, including 10 versions of UCB Japan’s antiepileptic Vimpat (lacosamide) and two of AstraZeneca’s SGLT2 inhibitor Forxiga (dapagliflozin), according to an official gazette.…
To read the full story
Related Article
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
- Vimpat Generics Win Added Use, Clearing Path for Full-Label Launch
December 4, 2025
- Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
- AGs Identified for 4 Brands in Latest Generic Approvals, Including Bonviva and Epadel
August 19, 2025
- Espha to Launch Authorized Generic of Zytiga in December
August 19, 2025
- Nipro Secures AG for Forxiga, Sawai and Teva Takeda Go Without Hydrate
August 18, 2025
- Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
REGULATORY
- MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
- Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
- Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
April 28, 2026
- Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…